Education
About Us
Working with TipRanks
Follow Us
Idorsia Ltd (CH:IDIA)
:IDIA
Top Page
Idorsia Ltd
(IDIA)
Rating:53Neutral
Price Target:
CHF3.50
▲(7.36% Upside)
Idorsia Ltd (IDIA) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF713.53M
Dividend YieldN/A
Average Volume (3M)1.61M
Price to Earnings (P/E)―
Beta (1Y)2.79
Revenue Growth57.35%
EPS Growth-474.25%
CountryCH
Employees636
SectorHealthcare
Sector Strength37
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.20
Shares Outstanding226,136,540
10 Day Avg. Volume2,176,028
30 Day Avg. Volume1,606,177
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF2.20Price Target Upside-32.52% Downside
Rating ConsensusHold
Number of Analyst Covering1
Idorsia Ltd Business Overview & Revenue Model
Company DescriptionIdorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
How the Company Makes MoneyIdorsia Ltd generates revenue primarily through the development and commercialization of pharmaceutical products. The company earns money by selling its proprietary drugs and through licensing agreements with other pharmaceutical companies. Idorsia may also receive milestone payments and royalties from its partners based on the successful development and commercialization of collaborative projects. Strategic collaborations and partnerships play a significant role in the company's revenue generation, enhancing its research capabilities and market reach.
Idorsia Ltd Earnings Call Summary
Earnings Call Date:Jul 30, 2025
(Q2-2025)
| % Change Since: 20.30%|
Next Earnings Date:Oct 30, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong growth in QUVIVIQ's sales and improvements in operating results, along with positive developments in strategic partnerships and financial stability. However, challenges persist with flat U.S. sales, reliance on regulatory processes, and liquidity constraints.Q2-2025 Updates
Positive Updates
Strong Commercial Performance of QUVIVIQ
QUVIVIQ net sales in the first half of 2025 more than doubled compared to last year, rising from CHF 23 million to CHF 56 million, driven by Europe and Canada.
Improvement in Non-GAAP Operating Results
Non-GAAP operating results improved significantly from a loss of CHF 170 million in the first half of 2024 to a loss of CHF 15 million in the first half of 2025.
Expansion of Global Footprint
QUVIVIQ's global footprint is expanding with availability in North America, Europe, Japan, and soon China. Public reimbursement has been secured in key European markets.
Financial Stability and Cash Runway Extension
Idorsia secured additional financial stability with the extension of their cash runway to the end of 2026 through a CHF 150 million funding facility.
Positive Feedback for TRYVIO
TRYVIO's FDA approval with the removal of REMS requirement, making it easier to prescribe and distribute, alongside its efficacy and safety profile in patients with comorbid conditions.
Negative Updates
Flat Sales in the U.S. Market
Sales of QUVIVIQ in the U.S. remained relatively flat despite a reduction in sales and marketing costs and a streamlined commercialization approach.
Dependence on Regulatory Processes
The potential descheduling of the DORA class is still pending, with timelines for FDA and DEA processes being uncertain and impacting future market potential.
Limited Liquidity
Liquidity at the end of June 2025 was CHF 72 million, highlighting the company's reliance on future cash inflows from milestones and the newly secured funding facility.
Company Guidance
In the call, Idorsia provided detailed guidance for its fiscal performance, emphasizing several key metrics. The company's net sales for the first half of 2025 experienced significant growth, with QUVIVIQ sales more than doubling from CHF 23 million to CHF 56 million, driven by strong demand in Europe and Canada. The non-GAAP operating result improved markedly, reducing losses from CHF 170 million to CHF 15 million. The company also achieved a U.S. GAAP net income of CHF 52 million, supported by a strategic cost-saving initiative that cut operational costs by nearly CHF 50 million compared to the previous year. Additionally, Idorsia extended its cash runway to the end of 2026 and maintained an unchanged guidance for its Idorsia-led business, projecting sales of CHF 130 million and a non-GAAP EBIT loss of CHF 175 million. The company aims to reach commercial profitability in 2026 and overall profitability by the end of 2027.Idorsia Ltd Financial Statement Overview
Summary
Idorsia Ltd faces significant financial challenges with consistent losses and high leverage. The negative profitability metrics and cash flow issues indicate operational inefficiencies, with negative equity and high debt levels further straining financial health.Income Statement
Idorsia Ltd's revenue has seen fluctuations with a noticeable decline of 26.19% from 2023 to 2024. The company consistently reports negative EBIT and net income, indicating ongoing operational challenges. The negative gross profit margin in 2024 suggests cost structure issues. Overall, the company struggles with profitability, reflected in the negative margins.40
Negative
Balance Sheet
The balance sheet shows a negative stockholders' equity, which raises concerns about financial stability. The debt-to-equity ratio is not calculable due to negative equity, but the high total debt level is a potential risk. The equity ratio is negative, indicating that liabilities exceed assets, which is concerning for investors.30
Negative
Cash Flow
Operating cash flow remains negative, indicating challenges in generating cash from operations. However, there is a positive trend in free cash flow from 2023 to 2024, though it remains negative. The free cash flow to net income ratio is not favorable, reflecting difficulties in managing cash effectively.45
Neutral
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 112.51M | 152.39M | 97.10M | 35.35M | 71.76M |
| Gross Profit | -67.08M | 145.24M | 90.84M | 17.32M | -309.32M |
| EBITDA | -319.49M | -254.55M | -783.09M | -588.84M | -420.64M |
| Net Income | -263.76M | -297.92M | -827.90M | -634.60M | -445.12M |
Balance Sheet | |||||
| Total Assets | 505.89M | 500.00M | 904.18M | 1.48B | 1.44B |
| Cash, Cash Equivalents and Short-Term Investments | 124.36M | 157.82M | 476.32M | 1.04B | 1.01B |
| Total Debt | 1.26B | 1.20B | 1.23B | 1.16B | 637.99M |
| Total Liabilities | 1.72B | 1.47B | 1.57B | 1.38B | 849.88M |
| Stockholders Equity | -1.21B | -968.72M | -660.96M | 104.20M | 585.48M |
Cash Flow | |||||
| Free Cash Flow | -373.23M | -638.69M | -886.17M | -620.83M | -373.95M |
| Operating Cash Flow | -370.23M | -629.30M | -859.11M | -589.89M | -364.67M |
| Investing Cash Flow | 305.06M | 632.61M | 743.90M | -53.26M | -607.13M |
| Financing Cash Flow | 26.11M | -197.00K | 162.31M | 604.15M | 850.08M |
Idorsia Ltd Technical Analysis
Positive
3.26
Price Trends
2.27
Positive
1.72
Positive
1.33
Positive
Market Momentum
0.30
Negative
65.12
Neutral
71.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:IDIA, the sentiment is Positive. The current price of 3.26 is above the 20-day moving average (MA) of 2.74, above the 50-day MA of 2.27, and above the 200-day MA of 1.33, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 65.12 is Neutral, neither overbought nor oversold. The STOCH value of 71.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:IDIA.
Idorsia Ltd Peers Comparison
Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | CHF678.21M | 8.37 | ― | 32.30% | 631.04% | ||
64 Neutral | CHF137.53M | 9.90 | ― | 450.19% | ― | ||
53 Neutral | CHF713.53M | ― | ― | 57.35% | -474.25% | ||
52 Neutral | CHF119.71M | ― | -40.40% | ― | -66.82% | 4.14% | |
50 Neutral | AU$2.60B | 3.64 | -58.14% | 2.69% | 36.37% | 13.78% | |
48 Neutral | CHF184.14M | 2.58 | -93.91% | ― | -62.17% | -166.33% |
* Healthcare Sector Average
Performance Comparison
CH:IDIA
Idorsia Ltd
3.17
1.07
50.95%
CH:MOLN
Molecular Partners AG
2.97
-2.55
-46.19%
CH:BSLN
Basilea Pharmaceutica
55.70
17.50
45.81%
CH:NWRN
Newron Pharmaceuticals SpA
6.89
-0.31
-4.31%
CH:SANN
Santhera Pharmaceuticals Holding
14.10
5.03
55.46%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.